Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Prep: Cook: Serves:

The advanced Parkinson’s treatment Duodopa has been rejected for routine use on the NHS in Scotland, sparking concerns among charities and health professionals.

The Scottish Medicines Consortium (SMC) said it was unable to approve of Duodopa, due to questions raised over its cost-effectiveness.

Dr Alan MacDonald, vice chairman of SMC, said: “The Committee was unable to accept co-careldopa intestinal gel (Duodopa) for the routine treatment of advanced Parkinson’s disease because of uncertainty about the clinical benefits the medicine would provide for this patient group in relation to its cost.”

Duodopa, which can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working. The gel treatment is administered to the intestine via pump and a tube and requires the patient to undergo surgery – it is estimated to cost around £28,000-per-year per patient and was approved for use by the NHS in England in July 2015.

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

Kim Petrie: “How I raised $250,000 for Parkinson’s research”

Kim Petrie tells us how she raised $250,000 to fight Parkinson’s

Parkinson’s: the “frenemy” within

We spoke to the creator of ‘When Life Gives You Parkinson’s’

‘Which Way Up’: documentary following painter John McLean

UK screening of film about painter with Parkinson’s, John McLean

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…

Students develop wearable device to track Parkinson’s tremors

A wearable device has been developed to monitor Parkinson’s tremors and their severity through the tracking of body movements. The device – Tremor Tracker – was created by two students, Julie Gaudin and Elizabeth Hummel, at Louisiana Tech University, US, as part of a design class project. The students designed an algorithm using data recorded from volunteer participants at Rock Steady, a boxing programme for people with Parkinson’s. They then applied the algorithm to a GENEActiv, a wrist-worn device that has been scientifically validated for clinical research. Hummel, co-creator of the Tremor Tracker, said: “Through supervised machine learning, the device predicts whether a patient’s tremors are parkinsonian or non-parkinsonian, as well as the severity of these tremors. A quantitative analysis of parkinsonian tremors provides a more detailed disease state.”

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

Reawakening dormant neurons could help reverse Parkinson’s motor symptoms, researchers in South Korea have found. While Parkinson’s is typically believed to be caused by neuronal death, a new study – published in ‘Current Biology’ journal – suggests that dormant neurons could be another cause. After completing an animal test – which treated the subjects with two compounds that block dopamine-producing neurons from becoming dormant – the researchers found these neurons to be “awakened”, allowing them to resume dopamine production. The researchers hope that this will lead to a disease-modifying treatment, especially for people in the early stages of Parkinson’s. Hoon Ryu, a senior author of the study and researcher at KIST Brain Science Institute, South Korea, said: “This research refutes the common belief that there is no disease-modifying treatment for Parkinson’s due to its basis on neuronal cell death.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Comments
This field is for validation purposes and should be left unchanged.

Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

Kim Petrie: “How I raised $250,000 for Parkinson’s research”

Interviews

Parkinson’s: the “frenemy” within

Perspectives

‘Which Way Up’: documentary following painter John McLean

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

Kim Petrie: “How I raised $250,000 for Parkinson’s research”

Interviews

Parkinson’s: the “frenemy” within

Perspectives

‘Which Way Up’: documentary following painter John McLean

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

Sign in